- Opill®, the first ever daily birth control pill
available without a prescription in the
United States, will be available in-store and online at
retailers nationwide in the coming weeks and for pre-order from
select retailers beginning this week
- To maximize the impact and accessibility of Opill®,
Perrigo has sought to ensure both the affordability and
availability of Opill® on shelves across the country and
online
DUBLIN and GRAND RAPIDS, Mich.,
March 4,
2024 /PRNewswire/ -- Perrigo Company plc (NYSE:
PRGO), a leading provider of Consumer Self-Care Products,
today announced that Opill® has shipped to major
retailers and pharmacies and will be available on shelves
nationwide and online later this month. Approved by the U.S. Food
and Drug Administration (FDA) for OTC use for all ages in
July 2023, Opill® is the
first-ever daily birth control pill available without a
prescription in the U.S.
Experience the full interactive Multichannel News Release
here:
https://www.multivu.com/players/English/9252151-perrigo-commences-shipments-of-opill-to-retailers-nationwide/
Opill® is now available for pre-order from select
online retailers and is expected to be on store shelves at major
retailers nationwide in the coming weeks. Consumers will have the
opportunity to purchase Opill® in a variety of sizes in
stores to best meet their needs, including one-month and
three-month packs, with a manufacturer's suggested retail price
(MSRP) of $19.99 and $49.99, respectively. Additionally,
Opill® will be available for purchase at Opill.com at a
price of $49.99 for a three-month
supply and $89.99 for a six-month
supply.
"The availability of an oral contraceptive without a
prescription is a truly groundbreaking milestone in reproductive
health," said Melissa J. Kottke, MD,
MPH, MBA, obstetrician-gynecologist in Atlanta, GA*. "Progestin-only pills have been
a trusted contraceptive option for decades, yet obtaining a
prescription for birth control pills creates unnecessary barriers
for many. Creating additional opportunities for contraceptive
access is critical in helping people reach their reproductive
goals."
When taken as directed, Opill® is 98%
effective(1), making it the most effective birth control
method available OTC(2). Almost half (45%) of the 6.1
million pregnancies in the U.S. each year are unintended, and for
many, there are barriers to accessing more effective birth control
options until now only available by prescription—including
scheduling a provider visit, transportation and cost barriers or
lack of insurance. Opill® can benefit a broad
reproductive age population who want a safe and effective option to
avoid pregnancy that is easy and convenient to access. Those who
face barriers to initiating use of effective methods and continuing
consistent use once started can benefit the most from
Opill®.
"At Perrigo, we've been working to make lives better through
trusted health and wellness solutions that are accessible to all
for more than 130 years and that purpose is especially important
when we think about reproductive health," said Triona Schmelter, Perrigo Executive Vice
President & President, Consumer Self-Care Americas. "We
champion the right of women and people to determine their own
sexual health journey and the availability of Opill®
over-the-counter is truly a historic moment of which our entire
organization can be proud."
To maximize the impact and accessibility of Opill®,
Perrigo has sought to ensure both the affordability and
availability of Opill® on major retailers' shelves
across the country and online.
"We are pleased that so many retailers have embraced carrying
Opill® to help ensure nationwide access to the product
and are happy that we are able to offer Opill® on our
website at a cost of less than $20
per month," said Sara Young, Perrigo
Senior Vice President and Chief Commercial Officer, Consumer
Self-Care Americas. "A cost-assistance program will also be
available in the coming weeks to help qualified low-income,
uninsured individuals obtain Opill® at low or no
cost."
Opill® may also be eligible to be paid or reimbursed
through Flexible Spending or Health Savings Accounts (also known as
FSAs/HSAs). OTC drugs are now generally reimbursable under HSA and
FSA plans, subject to the specific details and limitations of
individual employers' plans.
Nearly 50 years of use and scientific evidence demonstrate that
progestin-only pills such as Opill® are effective
at preventing pregnancy and are safe for most women to use. OTC
oral contraception has support from major medical organizations,
including the American College of Obstetricians and
Gynecologists, the American Medical
Association and the American Academy of Family
Physicians.
To learn more about Opill® or the Opill®
Cost Assistance Program, visit Opill.com or follow
@opill_OTC on Instagram, TikTok, Facebook, Threads and
X.
* Melissa J. Kottke,
MD, MPH, MBA served as a paid consultant during the FDA approval
process for Perrigo in 2023.
(1) Opill® over-the-counter
[Consumer Information Leaflet]. Dublin, Ireland: Perrigo Co,;
2023.
(2) Trussell et al, Contraceptive
Technology. 21st ed. 2018.
About Opill®
Opill® is the first ever and only over-the-counter
birth control pill available in the
United States. It is a progestin-only daily oral
contraceptive that's safe and effective when used as directed to
help prevent pregnancy. Do not use Opill® if you have or
ever had breast cancer. See Opill® Drug Facts label for
list of warnings. Opill® is not an emergency
contraceptive (morning after pill) and won't prevent pregnancy when
used after unprotected sex. It also doesn't protect against
HIV/AIDS or other sexually transmitted diseases (STDs). For more
information, please visit www.opill.com or follow
@opill_OTC on Instagram, TikTok, Facebook, Threads and
X.
About Perrigo
Perrigo Company plc (NYSE: PRGO), is a leading provider
of Consumer Self-Care Products and
over-the-counter (OTC) health and wellness solutions that enhance
individual well-being by empowering consumers to proactively
prevent or treat conditions that can be self-managed. Visit Perrigo
online at www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release relate to future events
and may therefore be considered "forward-looking statements".
Forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause the actual
results, levels of activity, performance or achievements of the
Company or its industry to be materially different from those
expressed or implied by such statements. Often such factors may be
beyond the Company's control, including the availability of raw
materials, labor or manufacturing issues, supply chain challenges,
actions or omissions by distributors and retailers, market
acceptance of new products, regulatory or legislative action, third
party litigation, and other unforeseen issues. The foregoing and
other important factors, including those discussed under "Risk
Factors" in the Company's Form 10-K for the year ended December 31, 2022, as well as the Company's
subsequent filings with the United States Securities and Exchange
Commission, could potentially impact the timing and availability of
Opill® at retailers in the United
States, and may cause actual results, performance or
achievements to differ materially from those expressed or implied
by these forward-looking statements. The forward-looking statements
in this press release are made only as of the date hereof, and
unless otherwise required by applicable securities laws, the
Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Contact
Media:
All Opill®-related media inquiries to be directed to:
press@opill.com
Investors:
Bradley
Joseph
Vice President, Global Investor Relations & Corporate
Communications
(269) 686-3373
bradley.joseph@perrigo.com
Nicholas Gallagher
Senior Manager, Global Investor Relations & Corporate
Communications
(269) 686-3238
nicholas.gallagher@perrigo.com
View original
content:https://www.prnewswire.com/news-releases/perrigo-commences-shipments-of-opill-to-retailers-nationwide-empowering-millions-to-enter-a-new-era-of-reproductive-health-access-in-the-united-states-302077710.html
SOURCE Perrigo Company plc